Skip to main content

Table 8 Analysis of Poisson’s regression of the effects of the deployment of DAMNP and CATS on the prevalence of medicines that are within the SUS formulary, outside the SUS formulary with a therapeutic alternative and without therapeutic alternative available by the SUS

From: Institutional strategies as a mechanism to rationalize the negative effects of the judicialization of access to medicine in Brazil

VariablesMedicines within the SUS formularycMedicines outside the SUS formulary with a therapeutic alternativecMedicines outside the SUS formulary without a therapeutic alternativec
APRa (95.0% CI)bpAPRa (95.0% CI)bpAPRa (95.0% CI)bp
 Before deployment1.00 1.00 1.00 
 After deployment1.07 (0.93–1.24)0.3071.38 (0.80–1.29)0.8670.83 (0.63–1.34)0.183
 Before deployment1.00 1.00 1.00 
 After deployment0.81 (0.67–0.98)0.0321.38 (1.07–1.78)0.0110.97 (0.70–1.34)0.866
  1. aAdjusted Prevalence ratio; bConfidence interval of 95%; cModel adjusted according to the origin of the prescription, DAMNP and CATS. dDepartment of Assessment of Non-Standardized Medicines; eTechnical Chamber of Health Assessment